ArticleDrug design, development and therapy2026
Comparative Efficacy of Triamcinolone versus Dexamethasone in Local Injection for Stenosing Tenosynovitis of the Metacarpophalangeal Joint: A Retrospective Cohort Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Local glucocorticoid injection is first-line therapy for stenosing tenosynovitis. However, the comparative efficacy of lipophilic sustained-release triamcinolone versus hydrophilic short-acting dexamethasone remains underexplored. This study aimed to compare clinical outcomes of triamcinolone versus dexamethasone in metacarpophalangeal joint injection, with hypothesis-generating exploration of how differential pharmacokinetics may influence efficacy and recurrence. Methods: This retrospective cohort study included adult patients receiving first-time local injection for stenosing tenosynovitis ranging from February 2021 to January 2025. Patients were divided into triamcinolone (10-20 mg + lidocaine) and dexamethasone (4 mg + lidocaine) groups. Propensity score matching (1:1) controlled for confounding. The primary outcome was 3-month overall efficacy (Quinnell grade I). Secondary outcomes included recurrence, second injection rate, surgical conversion, and local adverse events. Results: After matching 97 patients per group, baseline characteristics were balanced. At 3 months, triamcinolone demonstrated superior efficacy (82.5% vs 63.9%, P=0.004). Triamcinolone also showed lower 6-month recurrence (12.5% vs 27.4%, P=0.009), second injection rate (8.2% vs 19.6%, P=0.021), and surgical conversion (4.1% vs 13.4%, P=0.024). Fat atrophy was numerically higher with triamcinolone (9.3% vs 3.1%, P=0.072). We hypothesize that the sustained-release depot effect of triamcinolone may enable prolonged modulation of the inflamed A1 pulley microenvironment, though this mechanistic interpretation requires prospective validation. Conclusion: In this retrospective matched cohort, triamcinolone was associated with superior 3-month efficacy and lower recurrence compared to dexamethasone. These findings are hypothesis-generating and warrant prospective dose-controlled confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.